Skip to content
You are now leaving to visit

Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer’s Disease

Antisense drug designed to reduce tau protein in the CNS Ionis earns $10 million milestone payment from Biogen CARLSBAD, Calif. , Oct. 13, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has initiated a Phase 1/2a clinical study of IONIS-MAPT Rx in patients